Skip to Main Content

1,696

Views

4

CrossRef citations to date

0

Altmetric

Original Article

Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance

Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan; View further author information

,

Tomohiro HirosePfizer Japan Inc., Tokyo, Japan; Correspondence[email protected]
View further author information

,

Yutaka EndoPfizer Japan Inc., Tokyo, Japan; View further author information

,

Noriko SugiyamaPfizer Japan Inc., Tokyo, Japan; View further author information

,

Yuri FukumaPfizer Japan Inc., Tokyo, Japan; View further author information

,

Yosuke MorishimaPfizer Japan Inc., Tokyo, Japan; View further author information

,

Naonobu SugiyamaPfizer Japan Inc., Tokyo, Japan; View further author information

,

Noritoshi YoshiiPfizer Japan Inc., Tokyo, Japan; View further author information

,

Nobuyuki MiyasakaDepartment of Rheumatology, Tokyo Medical & Dental University, Tokyo, Japan; View further author information

&

Takao KoikeHokkaido Medical Center for Rheumatic Diseases, Sapporo, JapanView further author information